Impact of parent organizations in Duchenne muscular dystrophy research: maternal activism as a driver of change

Coral-Vázquez RM, López-Hernández LB, Ruano-Calde-

rón LA, Gómez-Díaz B, Fernández-Valverde F, Bahena-

Martínez E. Distrofi as musculares en México: un enfoque

clínico, bioquímico y molecular. Revista de Especialidades

Médico-Quirúrgicas. 2010; 15 (3): 152-160.

Biggar WD. Duchenne muscular dystrophy. Pediatr Rev.

; 27: 83-88.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR,

Cripe L et al. Diagnosis and management of Duchenne

muscular dystrophy, part 1: diagnosis and pharmaco-

logical and psychosocial management. Lancet Neurol.

; 9: 77-93.

Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby

K, Straub V. Prevalence of genetic muscle disease in

Northern England: in-depth analysis of a muscle clinic

population. Brain. 2009; 132: 3175-3186.

Reséndiz Juárez G. El abordaje familiar en el contexto

de la discapacidad. Algunas consideraciones para esta-

blecer relaciones entre el personal de salud y la familia

del paciente. Investigación en Discapacidad. 2013; 2:

-27.

Abi Daoud MS, Dooley JM, Gordon KE. Depression in

parents of children with Duchenne muscular dystrophy.

Pediatr Neurol. 2004; 31: 16-19.

Plumridge G, Metcalfe A, Coad J, Gill P. Family commu-

nication about genetic risk information: particular issues

for Duchenne muscular dystrophy. Am J Med Genet A.

; 152A: 1225-1232.

Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the

protein product of the Duchenne muscular dystrophy

locus. Cell. 1987; 51: 919-928.

López-Hernández LB, van Heusden D, Soriano-Ursúa

MA, Figuera-Villanueva L, Vázquez-Cárdenas NA,

Canto P et al. Genotype-phenotype discordance in a

Duchenne muscular dystrophy patient due to a novel

mutation: insights into the shock absorber function of

dystrophin. Rev Neurol. 2011; 52: 720-724.

Batchelor CL, Winder SJ. Sparks, signals and shock

absorbers: how dystrophin loss causes muscular dys-

trophy. Trends Cell Biol. 2006; 16: 198-205.

López-Hernández LB, Vázquez-Cárdenas NA, Luna-

Padrón E. Duchenne muscular dystrophy: current

aspects and perspectives on treatment. Rev Neurol.

; 49: 369-375.

Abbs S, Tuffery-Giraud S, Bakker E, Ferlini A, Sejersen

T, Mueller CR. Best practice guidelines on molecular

diagnostics in Duchenne/Becker muscular dystrophies.

Neuromuscul Disord. 2010; 20: 422-427.

Mathews KD, Cunniff C, Kantamneni JR, Ciafaloni E,

Miller T, Matthews D et al. Muscular Dystrophy Surveil-

lance, Tracking, and Research Network (mD STArnet):

Case definition in surveillance for childhood-onset

Duchenne/Becker muscular dystrophy. J Child Neurol.

; 25: 1098-1102.

Goemans NM, Tulinius M, van den Akker JT, Burm BE,

Ekhart PF, Heuvelmans N et al. Systemic administration

of PRO051 in Duchenne’s muscular dystrophy. N Engl

J Med. 2011; 364: 1513-1522.

López-Hernández LB, Ayala-Madrigal ML, van Heusden

D, Estrada-Mena FJ, Canto P, Sandoval-Ramírez L et

al. Improvements in the diagnosis of dystrophinopathies:

what have we learnt in these last 20 years? Rev Neurol.

; 52: 239-249.

Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B,

Meza-Espinoza P, Ruano-Calderón LA, Fernández-

Valverde F et al. Immunodetection analysis of muscular

dystrophies in Mexico. Muscle Nerve. 2012; 45: 338-345.